News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Daily News Fewer Diabetic Complications Seen When NOACs Given for AF L.A. McKeown February 22, 2022
News Daily News No Increased Bleeding With Alteplase in Stroke Patients on DOACs: Registry Data Yael L. Maxwell February 15, 2022
News Conference News ISC 2022 ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis Todd Neale February 10, 2022
News Daily News DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis L.A. McKeown January 20, 2022
News Daily News Shorter Anticoagulation an Option for Young Patients With Provoked VTE Todd Neale January 11, 2022
News Daily News MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission Todd Neale December 29, 2021
News Daily News Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study Todd Neale December 27, 2021
News Daily News FDA Approves Two Additional Indications for Rivaroxaban in Children L.A. McKeown December 21, 2021
News Conference News AHA 2021 Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage Todd Neale November 19, 2021
News Daily News Rivaroxaban Again Linked to More Bleeding vs Other DOACs Caitlin E. Cox October 11, 2021
News Features When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles Todd Neale September 28, 2021
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021
News Daily News Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t Shelley Wood August 04, 2021
News Conference News HRS 2021 STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation Todd Neale July 29, 2021